Technical Analysis for NXTC - NextCure, Inc.

Grade Last Price % Change Price Change
grade D 16.57 -1.25% -0.21
NXTC closed down 1.25 percent on Monday, July 15, 2019, on 31 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A N/A Down
See historical NXTC trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Spinning Top Other -1.25%
NR7 Range Contraction -1.25%
NR7-2 Range Contraction -1.25%
Inside Day Range Contraction -1.25%
NR7 Range Contraction -2.59%
Inside Day Range Contraction -2.59%

Older signals for NXTC ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
NextCure, Inc., a biopharmaceutical company, engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase I/II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression for the treatment of ovarian cancer, non-small cell lung cancer, and renal cancer. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is based in Beltsville, Maryland.
Medicine Health Biopharmaceutical Cancer Clinical Medicine Immunotherapy Cancer Treatments Virotherapy Tumor Non Small Cell Lung Cancer Ovarian Cancer Treatment Of Ovarian Cancer Oncolytics Biotech Metastasis Metastatic Solid Tumors Halozyme Immune Related Diseases Yale University
Is NXTC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 22.75
52 Week Low 13.86
Average Volume 80,824
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 15.825
10-Day Moving Average 16.796
Average True Range 1.3798
ADX 25.04
+DI 16.1456
-DI 13.2379
Chandelier Exit (Long, 3 ATRs ) 14.3306
Chandelier Exit (Short, 3 ATRs ) 17.9994
Upper Bollinger Band 17.9875
Lower Bollinger Band 13.6625
Percent B (%b) 0.67
BandWidth 27.330174
MACD Line -0.1648
MACD Signal Line -0.4591
MACD Histogram 0.2943
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.21
Resistance 3 (R3) 17.27 17.11 17.10
Resistance 2 (R2) 17.11 16.95 17.08 17.07
Resistance 1 (R1) 16.84 16.85 16.76 16.78 17.03
Pivot Point 16.69 16.69 16.65 16.66 16.69
Support 1 (S1) 16.42 16.52 16.34 16.36 16.11
Support 2 (S2) 16.26 16.42 16.23 16.07
Support 3 (S3) 15.99 16.26 16.04
Support 4 (S4) 15.93